Potential Region-Specific Neuroprotective Effects of Kynurenine Administration in Healthy Rodents Using...

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• The tryptophan (TRP) metabolic pathway yields kynurenine (KYN) and serotonin (5-HT), crucial for central nervous system functions like neuroprotection and mood regulation.
• KYN production escalates with inflammation and cortisol, activating indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) to generate neuroactive metabolites.
• These metabolites, including kynurenic acid (KA), quinolinic acid (QA), and 3-hydroxykynurenine (3HK), are implicated in neuroprotection and neurological disorders.

Purpose of the Study:

• To investigate the impact of exogenous kynurenine (KYN) administration on the kynurenine pathway's activity.
• To quantify KYN metabolite concentrations and mRNA expression of key pathway enzymes and neurotrophic factors in rat brain tissue.
• To assess the distribution and neuroprotective or neurotoxic potential of KYN and its metabolites in the peripheral and central nervous systems.

Main Methods:

• Acute and chronic administration of kynurenine (100 mg/kg) or saline to Sprague-Dawley rats.
• Quantification of KYN and its metabolites (KA, QA, 3HK) in plasma and seven brain regions using liquid chromatography-mass spectrometry.
• Measurement of mRNA expression for IDO, TDO, BDNF, CREB, and IL-6 via RT-PCR.

Main Results:

• Exogenous KYN administration increased the KA/3HK ratio in multiple brain regions and the plasma KA/QA ratio, indicating peripheral neuroprotection.
• Reduced plasma and cerebellar KA/3HK ratios suggested region-specific neurotoxicity.
• The hippocampus showed the highest accumulation of KYN and its metabolite KA, suggesting a potential neuroprotective role in this region.

Conclusions:

• Exogenous KYN administration modulates the kynurenine pathway, with dose-dependent effects on metabolite ratios suggesting both neuroprotective and potentially neurotoxic outcomes.
• The hippocampus appears to be a key site for KYN and KA accumulation, highlighting its potential role in KYN-mediated neuroprotection.
• Further research is warranted to fully elucidate the complex regional effects and therapeutic potential of KYN administration in neurological contexts.